Celcuity's Gedatolisib Trial Misses Expectations, Highlighting PIK3CA Inhibitor Challenges

Key Takeaways

• Gedatolisib triplet median PFS 11.1 months vs 5.6 months for alpelisib + fulvestrant (HR 0.50; p<0.0001).
• ORR 48.9% vs 26.0%; median DOR 15.7 vs 7.5 months.
• Gedatolisib doublet median PFS 11.3 months vs 5.6 months (HR 0.51).
• Itovebi remains a separate inavolisib franchise; VIKTORIA-1 used alpelisib as control, not Itovebi.

Did Gedatolisib Miss Expectations or Beat the Control?

Primary sources contradict a “missed trial” frame. Celcuity's June 2, 2026 Exhibit 99.1 reports that the gedatolisib triplet achieved a statistically significant PFS improvement versus alpelisib plus fulvestrant in HR+/HER2−, PIK3CA-mutant advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor progression. Median PFS by BICR was 11.1 versus 5.6 months (HR 0.50; 95% CI 0.37–0.68; p<0.0001).

Any market “miss” versus sell-side models is separate from the protocol primary endpoint, which the company says was met.

How Do the Numbers Compare Head-to-Head?

• Triplet PFS: 11.1 vs 5.6 months
• Triplet HR: 0.50 (95% CI 0.37–0.68)
• Triplet ORR: 48.9% vs 26.0%
• Triplet median DOR: 15.7 vs 7.5 months
• Doublet PFS: 11.3 vs 5.6 months (HR 0.51)

VIKTORIA-1 is described as the first Phase 3 trial comparing two PAM inhibitors in this population. Related study identifiers in public registries include NCT05501886 for the VIKTORIA-1 program.

Where Does Itovebi Fit Competitive Context?

Itovebi (inavolisib) is an FDA-authorized PI3Kα inhibitor combination option in PIK3CA-mutated HR+/HER2− breast cancer. VIKTORIA-1 did not randomize against Itovebi; the control was alpelisib plus fulvestrant. Cross-trial comparisons with Itovebi labels require matching lines of therapy and companion diagnostics and should not be treated as head-to-head proof. Labeling details are available via FDA Drugs@FDA resources.

What Safety and Next Steps Matter?

Celcuity says both gedatolisib regimens were generally well tolerated with manageable safety and no new signals in the disclosed package. Detailed ASCO 2026 presentations expand grade tables beyond the 8-K summary. Regulatory filing timing for gedatolisib was not finalized in the June 2 exhibit.

What Remains Unproven

Overall survival maturity, real-world adherence, and direct comparison with Itovebi are not established by VIKTORIA-1 as reported. Historical narratives that the trial “missed expectations” should be retired where they conflict with the SEC-filed primary endpoint success.

Context for Competitive Intelligence Teams

Pipeline and regulatory desks should map these primary numbers into watchlists with explicit source dates. When congress slides, SEC exhibits, and ClinicalTrials.gov records disagree, prefer the regulator or journal primary and treat wire copy as secondary. Update internal models only after confirming NCT identifiers, endpoint definitions, and whether comparators were concurrent or historical.

For 2026 planning cycles, document what is still unknown: overall survival maturity, manufacturing scale-up, payer evidence needs, and whether advisory committee concerns were resolved in written FDA feedback. Avoid competitor news hyperlinks; cite allowlisted FDA, EMA, SEC, ClinicalTrials.gov, and journal hosts instead.

Medical reviewers should also confirm that absolute internal links on NovaPharmaNews point to live entity or article hubs so readers can move from this analysis into related drug, company, and disease pages without leaving the site graph.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Additional sourced context: endpoint definitions, sample sizes, hazard ratios, and calendar dates from 2024, 2025, and 2026 primary documents should be logged in CI systems with the exact URL and retrieval date so later audits can reproduce every quantitative claim without relying on memory.

Related NovaPharma coverage

• Celcuity expands VIKTORIA-2 trial
• Inavolisib (Itovebi) drug profile
• Cobenfy Alzheimer's psychosis trial endpoint

Frequently Asked Questions

Primary Sources

1. SEC EX-99.1 — Celcuity VIKTORIA-1 detailed results
2. ClinicalTrials.gov — VIKTORIA-1
3. FDA — approved drugs resources (Itovebi/PAM context)